Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Research paper from Europe PMC. Evidence status: source reported.

Published

2015-12-21

Source reference

MED:26718929

DOI

10.1016/s1470-2045(15)00489-1

Jurisdiction

Not assessed

Licence

Bibliographic metadata only; article rights retained

Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Sweeney CJ, Sydes MR, Tombal B, Tierney JF, STOpCaP Steering Group. · Lancet Oncol · meta-analysis; research support, non-u.s. gov't; research-article; systematic review; journal article · Found via: ClinicalTrials.gov result publication

Source: https://europepmc.org/article/MED/26718929. Captured 2026-10-24.

Limitations: Listed by a ClinicalTrials.gov registration as a result publication of that study, and fetched by its PubMed ID. The registry's listing is the sponsor's statement; it does not confirm which data the paper used. Preprints may not be peer reviewed.